Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic Kidney Disease (CKD) is a significant comorbidity among patients with prostate cancer (PCa), yet its burden and predictors remain underexplored in resource-limited settings.
We aimed to determine the incidence and predictors of CKD among patients with PCa at Mbarara Regional Referral Hospital (MRRH) in Southwestern Uganda.
A retrospective cohort study was conducted in the oncology unit of MRRH, a satellite center of the Uganda Cancer Institute, and 212 participants with a histologically diagnosed PCa and baseline estimated glomerular filtration rate (eGFR) of equal to or greater than 60 mL/min/1.73 m² who initiated PCa treatment between 2019 and 2022 were enrolled, and their serum creatinines were extracted over a period of 2 years for the development of CKD, defined as an eGFR of less than 60 mL/min/1.73 m² for at least 3 consecutive months as calculated by the CKD-EPI Formula 2021 using at least 2 serial serum creatinine measurements, and an incidence rate and 2-year cumulative incidence were calculated. Cox proportional hazards regression was used to identify predictors of CKD, and a Kaplan-Meier CKD survival curve was plotted in the data analysis software STATA version 17.
The mean (±SD) age of the participants was 73.6 ± 9.9 years, with 89.6%, 29.25 %, 8.49%, and 14.62% having advanced PCa, hypertension, diabetes mellitus, and a prostate-related surgery at
baseline, respectively. The mean (±SD) baseline eGFR, Gleason score, prostate-specific antigen, and hemoglobin were 83.09 ±16.38 mL/min/1.73 m², 8±1, 424.6 ±128.3 ng/dL, and 12.3 ±2.7 g/dL, respectively. 43 participants developed CKD during the study, with a 2-year cumulative incidence of CKD of 20.28% and an overall incidence rate of 11.9 per 1,000 person-months (95% CI: 8.85-16.1).
Multivariable analysis identified hypertension (adjusted hazard ratio [aHR]: 1.90, 95% CI: 1.01-3.60, p=0.048) and anemia defined as hemoglobin of less than 13.0 g/dL (aHR: 2.63, 95% CI: 1.27-5.03, p=0.008 as independent predictors of CKD development.
CKD is a common complication among patients with PCa at MRRH, with hypertension and anemia being significant predictors. Early detection and intensive management of these predictors
may help mitigate CKD progression in this population. Further prospective studies are warranted to develop risk-stratification models and explore other biomarkers of CKD. (Supported by the MUST
Internal Medicine Postgraduate Research Fund. Approval no. MUST-2024-1606).
